Videos

Yana Etkin, MD,  presented an in-depth review of strategies for identifying and managing failing DVA, emphasizing that long-term success depends not only on creating the DVA circuit but also on maintaining its patency through vigilant...

Dr Eric Secemsky presented a review of the evidence supporting contemporary medical management for patients with PAD and CLTI, emphasizing that pharmacologic therapy remains an essential pillar of reducing cardiovascular events.

During a Thursday afternoon session at the Amputation Prevention Symposium 2026, Ralf Langhoff, MD, asked attendees to reconsider when retrograde access should be used for chronic total occlusion (CTO) interventions.

Dr Ramon L. Varcoe presented an update on bioresorbable BTK technology, highlighting the growing body of evidence supporting the Esprit™ BTK drug-eluting resorbable scaffold (Abbott Cardiovascular) for the treatment of CLTI.

Dr Pradeep K. Nair presented the clinical rationale, engineering design, pivotal clinical data, and early real-world experience with the Santreva-ATK Endovascular Revascularization Catheter (AngioSafe).

This presentation examined the evolving evidence supporting the SELUTION SLR sirolimus drug-eluting balloon (Cordis) as a treatment strategy for femoropopliteal and BTK PAD, with particular emphasis on complex CLTI.

Tim Wittig, MD, presents the primary outcomes from the MOTIV BTK Trial, which evaluated the safety and efficacy of the sirolimus-eluting bioresorbable scaffold MOTIV BTK.

Dr Eric Scott presents presents a case-based discussion on how advanced vascular imaging should guide the decision between an endovascular-first or surgical bypass-first approach for patients with PAD and CLTI.

Jos C. van den Berg, MD, PhD, presents findings from a pilot health economic analysis conducted in Germany that provides an important framework for understanding the true societal cost of CLTI.